Molecular characterization of two novel antibacterial peptides inducible upon bacterial challenge in an annelid, the leech Theromyzon tessulatum

Two novel antimicrobial peptides named theromacin and theromyzin were isolated and characterized from the coelomic liquid of the leech Theromyzon tessulatum. Theromacin is a 75-amino acid cationic peptide containing 10 cysteine residues arranged in a disulfide array showing no similarities with other known antimicrobial peptides. Theromyzin is an 86-amino acid linear peptide and constitutes the first anionic antimicrobial peptide observed in invertebrates. Both peptides exhibit activity directed against Gram-positive bacteria. Theromacin and theromyzin cDNAs code precursor molecules containing a putative signal sequence directly followed by the mature peptide. The enhancement of theromacin and theromyzin mRNA levels has been observed after blood meal ingestion and upon bacterial challenge. In situ hybridization revealed that both genes are expressed in large fat cells in contact with coelomic cavities. Gene products were immunodetected in large fat cells, in intestinal epithelia, and at the epidermis level. In addition, a rapid release of the peptides into the coelomic liquid was observed after bacterial challenge. The presence of antimicrobial peptide genes in leeches and their expression in a specific tissue functionally resembling the insect fat body provide evidence for the first time of an antibacterial response in a lophotrochozoan comparable to that of holometabola insects.

Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.

El resumen se deja sin traducir para conservar la redacción original de los autores.

Theromacin (75 amino acids, cationic, 10 cysteines) and theromyzin (86 amino acids, the first anionic antimicrobial peptide reported in invertebrates) were isolated from the coelomic liquid of the leech Theromyzon tessulatum. Both are active against Gram-positive bacteria, and their mRNA levels rise after bacterial challenge.

Explore cómo esta investigación se conecta con la práctica clínica

Más estudios revisados por pares en la categoría «Farmacología salival».

• Sanguijuelas medicinales e hirudoterapia — Gödekmerdan A et al. (2011)
• Peroxidación de lípidos salivales en pacientes con síndrome poscovid durante la hirudoterapia — Serikbayeva S et al. (2024)
• Terapia con sanguijuelas medicinales en síndromes dolorosos: una revisión narrativa — Koeppen D, Aurich M, Rampp T (2014)
• Efectos inmunomoduladores del extracto de saliva de la sanguijuela medicinal sobre macrófagos activados in vitro — Ayhan H et al. (2024)
• Inhibidores de proteinasas de la sanguijuela medicinal Hirudo medicinalis — Baskova I, Zavalova L (2001)
• Polifuncionalidad de la destabilasa, una lisozima de una sanguijuela medicinal — Baskova I, Zavalova L (2008)
• Hazlo doble: identificación y caracterización de una hirudina en tándem de la sanguijuela medicinal asiática Hirudinaria manillensis — Lukas P et al. (2022)
• Use of the medicinal leech in the treatment of ear diseases — Seleznev K et al. (1992)
• La destabilasa recombinante de Hirudo medicinalis puede disolver coágulos sanguíneos humanos in vitro — Bobrovsky P et al. (2021)
• Efectos de la dispersión ambiental de nanotubos de carbono sobre un invertebrado acuático, Hirudo medicinalis — Girardello R et al. (2015)

Ver toda la investigación analizada por la ASH →